Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

Article Abstract:

A combination of a protease inhibitor and two nucleoside analogs can significantly reduce blood levels of HIV in people infected with the virus. These are all drugs that are used to treat HIV infection. Ninety-seven HIV patients were randomly assigned to take the protease inhibitor indinavir alone, the nucleoside analogs zidovudine and lamivudine, or all three drugs. All the patients had 20,000 copies or more of HIV RNA per milliliter of blood. These levels were reduced to less than 500 copies in 90% of those taking all three drugs, compared to 43% of those taking indinavir and none of those taking the nucleoside analogs.

Product/Service Evaluation, Measurement, HIV (Viruses), HIV, Zidovudine, Viremia, Lamivudine, Viral load, Indinavir (Medication)

---

Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS clinical trials group study A5095)

Article Abstract:

Metabolic changes are assessed after initiation of protease inhibitor (PI)-sparing regimes in antiretroviral-naive patients. The results have shown mild increases in glucose and decreases in insulin sensitivity in all regimens, whereas lipids are modestly higher in the 3-drug efavirenz (EFV)-containing arms and the metabolic dysfunctions of concern after the PI-sparing therapies are abnormal total cholesterol (TC) and lower high-density lipoprotein cholesterol (HDL-C) levels.

Science & research, Care and treatment, Research, Complications and side effects, Drug metabolism, Clinical report

---

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

Article Abstract:

A double-blind study, involving three antiretroviral regimens for the initial treatment of patients infected with HIV-1:zidovudine-lamivudine-abacavir, zidovudine-lamivudine plus efavirenz, and zidovudine-lamivudine-abacavir plus efavirenz, is presented.

Antiviral agents, Antiretroviral agents, Reverse transcriptase inhibitors

Similar abstracts:

• Abstracts: Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: Results from ACTG 384
• Abstracts: Trends in management and outcomes of patients with acute myocardial infraction complicated by cardiogenic shock
• Abstracts: Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: A randomized clinical trial. Effectiveness of Team-Managed Home-Based Primary Care: A Randomized Multicenter Trial

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.